EUVIMEDEUVIMED entdecken
Open Access

An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations

Michael Westberg iD, Yichi Su iD, Xinzhi Zou iD, Pinghan Huang iD, Arjun Rustagi iD, Jaishree Garhyan iD, Puja Bhavesh Patel, Daniel Fernandez iD, Yan Wu iD, Chenzhou Hao iD, Chieh-Wen Lo, Marwah Karim iD und 10 weitere

Science Translational Medicine · 13.03.2024 · 16 (738)

DOI: 10.1126/scitranslmed.adi0979 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 13.03.2024. Verfasst von Michael Westberg und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurobiology, Stanford University, Stanford, CA 94305, USA. Hauptthemen laut MEDLINE: COVID-19, Coronavirus 3C Proteases. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 147 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inhibitors of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (M pro ) such as nirmatrelvir (NTV) and ensitrelvir (ETV) have proven effective in reducing the severity of COVID-19, but the presence of resistance-conferring mutations in sequenced viral genomes raises concerns about future drug resistance. Second-generation oral drugs that retain function against these mutants are thus urgently needed. We hypothesized that the covalent hepatitis C virus protease inhibitor boceprevir (BPV) could serve as the basis for orally bioavailable drugs that inhibit SARS-CoV-2 M pro more efficiently than existing drugs. Performing structure-guided modifications of BPV, we developed a picomolar-affinity inhibitor, ML2006a4, with antiviral activity, oral pharmacokinetics, and therapeutic efficacy similar or superior to those of NTV. A crucial feature of ML2006a4 is a derivatization of the ketoamide reactive group that improves cell permeability and oral bioavailability. Last, ML2006a4 was found to be less sensitive to several mutations that cause resistance to NTV or ETV and occur in the natural SARS-CoV-2 population. Thus, anticipatory design can preemptively address potential resistance mechanisms to expand future treatment options against coronavirus variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Coronavirus 3C ProteasesHumansSARS-CoV-2MutationAntiviral AgentsProtease Inhibitors

Substanzen

3C-like proteinase, SARS-CoV-2Antiviral AgentsProtease InhibitorsCoronavirus 3C Proteases

Autor:innen und Institutionen

  • Department of Neurobiology, Stanford University, Stanford, CA 94305, USA.
  • Department of Chemistry, Aarhus University, 8000 Aarhus C, Denmark.
  • Interdisciplinary Nanoscience Center (iNANO), Aarhus University, 8000 Aarhus C, Denmark.
  • Institute for Translational Brain Research, State Key Laboratory of Medical Neurobiology, MOE Frontiers Center for Brain Science, Fudan University, Shanghai 200032, China.
  • Department of Bioengineering, Stanford University, Stanford, CA 94305, USA.
  • Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.

ORCID-Profile: Michael Westberg, Yichi Su, Xinzhi Zou, Pinghan Huang, Arjun Rustagi, Jaishree Garhyan, Daniel Fernandez, Yan Wu, Chenzhou Hao, Marwah Karim, Panatda Saenkham-Huntsinger, Vivian Tat, Aleksandra Drelich, Bi-Hung Peng, Shirit Einav, Chien-Te K Tseng, Catherine Blish, Michael Z Lin

Förderung

  • NIGMS NIH HHS
  • NIAID NIH HHS

Zitieren

APA

Westberg, M., Su, Y., Zou, X., Huang, P., Rustagi, A., Garhyan, J., Patel, P. B., Fernandez, D., Wu, Y., Hao, C., Lo, C. W., Karim, M., Ning, L., Beck, A., Saenkham-Huntsinger, P., Tat, V., Drelich, A., Peng, B. H., Einav, S., …, & Lin, M. Z. (2024). An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations. Science Translational Medicine, 16(738). https://doi.org/10.1126/scitranslmed.adi0979

Vancouver

Westberg M, Su Y, Zou X, Huang P, Rustagi A, Garhyan J, et al. An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations. Science Translational Medicine. 2024;16(738). doi:10.1126/scitranslmed.adi0979

BibTeX
@article{Westberg2024,
  author = {Westberg, Michael and Su, Yichi and Zou, Xinzhi and Huang, Pinghan and Rustagi, Arjun and Garhyan, Jaishree and Patel, Puja Bhavesh and Fernandez, Daniel and Wu, Yan and Hao, Chenzhou and Lo, Chieh-Wen and Karim, Marwah and Ning, Lin and Beck, Aimee and Saenkham-Huntsinger, Panatda and Tat, Vivian and Drelich, Aleksandra and Peng, Bi-Hung and Einav, Shirit and Tseng, Chien-Te K and Blish, Catherine and Lin, Michael Z},
  title = {An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations},
  journal = {Science Translational Medicine},
  year = {2024},
  volume = {16},
  number = {738},
  doi = {10.1126/scitranslmed.adi0979}
}
Kostenlos starten →